EMPA-REG OUTCOME: Consistent reduction in risk of cardiovascular outcomes and mortality with empagliflozin irrespective of sulphonylurea use at baseline

被引：0
|
作者：
Inzucchi, S. E. [1 ]
George, J. T. [2 ]
Fitchett, D. [3 ]
Mattheus, M. [2 ]
Janista, C. [2 ]
Zinman, B. [4 ]
机构：
[1] Yale Univ, Sch Med, Sect Endocrinol, New Haven, CT USA
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Therapeut Area Metab, Ingelheim, Germany
[3] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[4] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
来源：
DIABETIC MEDICINE | 2018年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P190
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [21] Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
    Zinman, Bernard
    Inzucchi, Silvio E.
    Lachin, John M.
    Wanner, Christoph
    Ferrari, Roberto
    Fitchett, David
    Bluhmki, Erich
    Hantel, Stefan
    Kempthorne-Rawson, Joan
    Newman, Jennifer
    Johansen, Odd Erik
    Woerle, Hans-Juergen
    Broedl, Uli C.
    CARDIOVASCULAR DIABETOLOGY, 2014, 13
  • [22] MEDIATORS OF THE EMPAGLIFLOZIN TREATMENT EFFECT ON KIDNEY OUTCOMES IN THE EMPA-REG OUTCOME TRIAL
    Jardine, M.
    Wanner, C.
    Nangaku, M.
    Kraus, B.
    Zinman, B.
    Mattheus, M.
    Hantel, S.
    Schumacher, M.
    Ohneberg, K.
    Schmoor, C.
    Inzucchi, S. E.
    NEPHROLOGY, 2021, 26 : 19 - 19
  • [23] Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial
    Fitchett, David
    Inzucchi, Silvio E.
    Zinman, Bernard
    Wanner, Christoph
    Schumacher, Martin
    Schmoor, Claudia
    Ohneberg, Kristin
    Ofstad, Anne Pernille
    Salsali, Afshin
    George, Jyothis T.
    Hantel, Stefan
    Bluhmki, Erich
    Lachin, John M.
    Zannad, Faiez
    ESC HEART FAILURE, 2021, 8 (06): : 4517 - 4527
  • [24] Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial
    Fitchett, David
    Inzucchi, Silvio E.
    Zinman, Bernard
    Wanner, Christoph
    Schumacher, Martin
    Schmoor, Claudia
    Ohneberg, Kristin
    Ofstad, Anne Pernille
    Salsali, Afshin
    George, Jyothis T.
    Hantel, Stefan
    Bluhmki, Erich
    Lachin, John M.
    Zannad, Faiez
    ESC HEART FAILURE, 2022, 8 (06): : 4517 - 4527
  • [25] EFFECT OF EMPAGLIFLOZIN ON CARDIOVASCULAR DEATH IN SUBGROUPS BYAGE: RESULTS FROM EMPA-REG OUTCOME
    D'Emden, M.
    Fitchett, D.
    Kis, Giljanovic S.
    Woerle, H.
    Zinman, B.
    Inzucchi, S.
    NEPHROLOGY, 2016, 21 : 58 - 58
  • [26] Empagliflozin and kidney outcomes in patients with or without heart failure at baseline: insights from the EMPA-REG OUTCOME trial
    Butler, J.
    Zannad, F.
    Fitchett, D.
    Zinman, B.
    Koitka-Weber, A.
    von Eynatten, M.
    Hehnke, U.
    George, J.
    Brueckmann, M.
    Cheung, A. K.
    Wanner, C.
    DIABETOLOGIA, 2018, 61 : S323 - S323
  • [27] How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
    Inzucchi, Silvio E.
    Zinman, Bernard
    Fitchett, David
    Wanner, Christoph
    Ferrannini, Ele
    Schumacher, Martin
    Schmoor, Claudia
    Ohneberg, Kristin
    Johansen, Odd Erik
    George, Jyothis T.
    Hantel, Stefan
    Bluhmki, Erich
    Lachin, John M.
    DIABETES CARE, 2018, 41 (02) : 356 - 363
  • [28] Effect of Empagliflozin on Cardiovascular Death in Subgroups by Age: Results from EMPA-REG Outcome
    Ridderstrale, Martin
    Toural, Elvira
    Fitchett, David
    Kis, Sanja Giljanovic
    Woerle, Hans J.
    Mattheus, Michaela
    Zinman, Bernard
    Inzucchi, Silvio E.
    DIABETES, 2016, 65 : A289 - A290
  • [29] Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis
    Scheen, Andre J.
    DIABETES & METABOLISM, 2016, 42 (02) : 71 - 76
  • [30] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
    Fitchett, David
    Zinman, Bernard
    Wanner, Christoph
    Lachin, John M.
    Hantel, Stefan
    Salsali, Afshin
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Inzucchi, Silvio E.
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    EUROPEAN HEART JOURNAL, 2016, 37 (19) : 1526 - 1534
12345